Clinical and Molecular Hepatology

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs: Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau; Clin Mol Hepatol 2025;31(1):e19-e20.
Published online October 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.0906

Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”: Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau; Clin Mol Hepatol 2025;31(1):e13-e14.
Published online September 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0682

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clinical and Molecular Hepatology.2025; 31(1): e98. CrossRef

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”: Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau; Clin Mol Hepatol 2024;30(4):978-981.
Published online August 5, 2024; DOI: https://doi.org/10.3350/cmh.2024.0565

Citations

Citations to this article as recorded by

Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease
Ziteng Wang, Wentao Tan, Jiali Huang, Qian Li, Jing Wang, Hui Su, Chunmei Guo, Hong Liu
Frontiers in Nutrition.2024;[Epub] CrossRef
Comparisons of Post-Load Glucose at Different Time Points for Identifying High Risks of MASLD Progression
Long Teng, Ling Luo, Yanhong Sun, Wei Wang, Zhi Dong, Xiaopei Cao, Junzhao Ye, Bihui Zhong
Nutrients.2024; 17(1): 152. CrossRef